Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Pair of Roche deals add allogeneic cell therapies, first-in-class fibrosis molecule

Deals provide substantial cash runway extensions for Poseida, Kiniksa

August 3, 2022 10:23 PM UTC

Roche spent more than $200 million in upfront payments to expand its interest in allogeneic cell therapies for cancer and add a first-in-class molecule for fibrosis.

On Wednesday, Poseida Therapeutics Inc. (NASDAQ:PSTX) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive rights and options to multiple allogeneic CAR T therapy programs, including P-BCMA-ALLO1, which is a BCMA-targeted CAR T therapy in Phase I testing to treat multiple myeloma; and P-CD19CD20-ALLO1, a dual-targeting CAR T against CD19 and CD20 that is expected to enter the clinic next year. The partners will also jointly discover and develop next-generation allogeneic CAR T therapies that Roche would have an option to license...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article